MedTrace Logo

Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography

NCT03806725 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-01-04

No results posted yet for this study

Summary

This study evaluates the safety of iodinated contrast medium administered to liver transplant candidates with decreased renal function undergoing coronary CT angiography. Incidence of post-contrast acute kidney injury in liver transplant candidates with decreased renal function and normal renal function will be compared.

Conditions

  • Acute Kidney Injury
  • Renal Insufficiency, Chronic
  • Contrast-induced Nephropathy
  • Liver Transplantation
  • Contrast Media

Interventions

DIAGNOSTIC_TEST

Intravenous administration of iodinated contrast medium for coronary CT angiography

Administration of iodinated contrast medium for coronary CT angiography

Sponsors & Collaborators

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-11-22
Completion
2022-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806725 on ClinicalTrials.gov